The interleukin-12B (IL12B) gene encodes the p40 chain of IL-12, a pro-inflammatory cytokine that antagonizes Th2 phenotype and, hence, may have a critical role in the pathogenesis of allergic asthma. In this report, we describe the identification of a novel IL12B promoter polymorphism (T-to-A exchange) at position À 536. The IL12B À 536AA genotype was significantly associated with asthma in the Chinese populations (P ¼ 0.011, odds ratio ¼ 2.227). The risk-associated A allele was linked to reduced expression of IL12B mRNA levels and IL12B production in asthmatic patients. Luciferase reporter assay provided evidence that risk-associated A allele reduced the promoter activity of IL12B gene compared with those of the promoter containing the protective T allele. We further observed that decreasing binding effects between the risk alleles A of IL12B and CCAAT/enhancer binding protein alpha (C/EBPa) through A allele sequence mediated streptavidin-conjugated agarose pulldown and biotin-labelled A allele mediated electrophoretic mobility shift assay. We also observed additive effects of the risk alleles of IL12B and decreased mRNA levels of C/EBPa in asthmatic patients. Therefore, we postulated that the presence of À 536A allele in IL12B promoter could predispose to the development of allergic asthma.
INTRODUCTION
Allergic asthma is a common and complex chronic inflammatory lung disease characterized by airway hyper-responsiveness in response to allergens, leading to smooth muscle constriction, excess mucous production and smooth muscle hyperplasia. 1, 2 These symptoms manifest as coughing, wheezing, breathlessness and chest tightness (Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma, 1987 2 ). The incidence of asthma ranges from 1-18% of individuals around the world, with B300 million people affected and accounts for B250 000 deaths every year. 3 A main goal of asthma research is to understand the genetic and environmental triggers for asthma and the factors that lead to variations in its natural history. Large-scale genome screens have identified several chromosomal regions, including chromosome 5q31-33, linked to the diagnosis of asthma. [4] [5] [6] The cytokine gene cluster is located on chromosome 5q31-33, and this region contains several potential candidate genes for asthma, including IL-3, IL-4, IL-5, IL-9, IL12B, IL-13, CD14 and the b2-adrenergic receptor. [4] [5] [6] Polymorphisms in several of these genes have been associated, in many populations, with asthma and total serum IgE. [7] [8] [9] The IL12B gene is a potential candidate for asthma because of its role in regulating Th1/Th2 responses by preferentially generating Th1 cells and IFN-g, while suppressing the release of Th2 cytokines such as IL-4 and IL-5.
10,11 IL-12 has two disulfidebonded polypeptide chains, a 35-kd chain encoded by IL12A on chromosome 3p12-q13 and a 40-kd chain encoded by IL12B on chromosome 5q31-33. 11 IL-12 deficiency thus skewed the immune system toward a Th2-type profile, which was thought to have a crucial role in the pathogenesis of airway inflammation observed in asthma. 12, 13 Several polymorphisms in the IL12B gene have been identified as causal single nucleotide polymorphism (SNP) for asthma susceptibility, including a promoter polymorphism of the IL12B gene in a cohort of Australian children. 9 In that study, asthmatic children carrying heterozygous polymorphisms had fourtimes higher possibility of having severe asthma when compared with homozygotes for either allele, even though the polymorphism was not associated with asthma per se. 9 Furthermore, IL-12 mRNA expression was significantly lower in bronchial biopsy specimens from allergic asthmatic patients compared with those from normal control subjects. 14, 15 However, it is still unclear that why the expression of IL-12 is reduced in asthmatic patients. This led us to the hypothesis that an IL12B promoter polymorphism was responsible for the reduced sensitivity of IL12B production for the inhibitory signal. Here, we describe the identification of such a polymorphism and its relation to asthma.
RESULTS
Identification of a T-to-A substitution at position À 536 of the IL12B promoter that is associated with allergic asthma The promoter À 1200 to þ 30 region of IL12B gene was analyzed by direct PCR sequencing, which allows determination of both alleles simultaneously. After identification of a nucleotide exchange (T to A) immediately among the consensus C/EBP transcription factor binding site at positions À 530 to À 538, we quickly screened the remainder of the samples, including 255 asthmatic patients and 144 healthy controls for the presence of this polymorphism. Analysis of allergic asthma patients and nonasthmatic controls, for the presence of the IL12B À 536T to A substitution (Table 1 and Supplementary Figure 1) , revealed a higher frequency of homozygous À 536AA carriers in the allergic asthma group (19/255) in contrast to 3/144 in the control group (P ¼ 0.011). However, the À 536AA genotypes were not related to total or specific serum IgE levels or bronchial hyper-responsiveness within the asthmatic patient group (data not shown). Furthermore, we confirmed that our association analysis of the promoter polymorphism À 536T4A in an independent casecontrol sample consisting of 103 individuals with allergic asthma and 105 normal controls from the Henan province of China (P ¼ 0.0042, Table 2 ).
We further examined the association between other SNPs of IL12B gene and asthma in our case-control study. Table 1 ). However, there was no significant association between these SNPs and allergic asthma after we performed the larger scale genotyping in 255 asthmatic patients and 144 health controls (Table 1) . These results demonstrated that promoter SNP À 536T4A of IL12B was associated with asthma in Chinese populations.
The À 536AA genotype is associated with decreased regulation of IL12B mRNA levels and IL12B production We next explored the association between promoter À 536T4A and IL12B expression. IL12B mRNA levels were determined by realtime PCR in 36 asthmatic patients and 28 healthy controls with known genotypes and available RNA samples (samples from five healthy subjects with AA genotypes were collected due to limited healthy subjects' blood samples). Compared with asthmatic individuals with the TT genotype, individuals with heterozygous TA genotype had lower and significantly low levels of IL12B (P ¼ 0.017; Figure 1a) . Furthermore, asthmatic individuals with AA genotype had the significantly lowest IL12B levels (P ¼ 0.005; Figure 1a ). There was lower expression of IL12B mRNA in healthy controls with AA genotypes compared with those of healthy subjects with TT genotypes (P ¼ 0.038, Figure 1a ). These results indicated that À 536T4A of IL12B may function by regulating the transcription activity and expression levels of IL12B.
We further detected the IL12B protein production levels among 36 asthmatic patients and 28 healthy controls carrying three different À 536T4A genotypes. We compared the IL12B production by ELISA among the corresponding subjects. In Figure 1b the distribution of the À 536 genotypes was indicated for both asthmatic patients and healthy controls. Asthmatic subjects homozygous for À 536AA displayed a significantly decreased relative inhibition of IL12B production compared with the À 536TT or TA genotypes in asthmatic group (P ¼ 0.015 and P ¼ 0.037, respectively). Similarly, there was a significant reduction of IL12B production in healthy controls with AA genotypes when compared with the À 536TT genotypes in healthy group (P ¼ 0.047, respectively). Taken together, these results demonstrated that the À 536AA genotype was associated with decreased regulation of IL12B both at mRNA levels and protein levels. Allelic difference of À 536T4A in IL12B promoter activity mediated by C/EBPa To explore molecular mechanisms of the association between À 536AA genotype and decreased IL12B expression, we examined whether the variant was functionally significant, by altering the IL12B promoter activity. We then generated reporter gene constructs containing both À 536A and À 536T allele and transfected Jurkat T cell lines with the reporter plasmids, so that the effect of each allele on the IL12B promoter activity could be evaluated in the context of the full-length promoter. First, the construct carrying the T allele had higher basal activity in Jurkat T cells than the construct carrying the risk-associated A allele (P ¼ 0.031, Figure 2 ). The finding was consistent with our previous observation of an association between reduced IL12B expression and asthma. Moreover, when the cells were activated by LPS and IFN-g after transfection, the induced activity of the promoter with the T allele remained higher ( Figure 2 ). Similarly, B50% reduction in the activity of the promoter with the risk-associated A allele was observed in Jurkat T cells under both rested, and LPS-and IFN-gactivated conditions ( Figure 2 ). Considering these data together, our reporter gene assay showed that the disease-associated A allele reduced the promoter activity of IL12B gene. We predicted a À 536T4A within the binding sites of C/EBP transcription factors on the IL12B promoter using TFsearch online (http://www.cbrc.jp/research/db/TFSEARCH.html).
Furthermore, we found that C/EBPa overexpresssion induces significant upregulation of IL12B promoter-mediated luciferase production (P ¼ 0.007). The A allele promoter of IL12B mediated less reporter activation (56%±4.3% of T allele-mediated luciferase ratio, P ¼ 0.011) than IL12B T allele promoter after C/EBPa overexpresssion. However, there was no significant difference with medium control on the reporter activation levels when transfected with C/EBPb, g expression vectors. Furthermore, knockdown of C/EBPa in Jurkat T cells could significantly decrease regulation of IL12B promoter-mediated luciferase production and the A allele promoter of IL12B mediated less activation than IL12B À 536T allele promoter after C/EBPa knockdown (Supplementary Figure 2) . Our results indicated that disease-associated A allele reduced the promoter activity of IL12B possibly through C/EBPa mediating transcription of IL12B.
The À 536T-to-A change results in decreased binding of nuclear protein C/EBPa We next assessed whether the allelic difference of promoter À 536T4A in regulatory activity was attributable to different binding affinity for C/EBPa. To examine the binding affinity more directly, we performed a promoter pulldown assay using streptavidin-conjugated agarose beads. When incubated with nuclear extracts from LPS-and IFN-g-activated Jurkat T cells, the biotin-labeled A probe bound less C/EBPa protein than the T probe, as demonstrated by western blotting analysis of total agarose beads-precipitated proteins with an anti-C/EBPa antibody (Figures 3a and b) . Taken together, these results demonstrate that promoter À 536T4A polymorphism alters C/EBPa binding, and the risk-associated A allele is less competent than the T allele in the regulation of IL12B expression.
To provide an explanation for the functional relevance of the À 536T-to-A change, we analyzed the binding of nuclear proteins to this region using electromobility shift assays. As probes, we used the C/EBP binding site containing either an A, or a T at Figure 1 . The À 536AA genotype is associated with decreased regulation of IL12B mRNA levels and IL12B production. (a) Quantitative realtime PCR of IL12B mRNA from peripheral blood lymphocyte cells from 36 allergic asthmatic patients and 28 controls carrying the main T/T, A/A genotypes and heterogeneous T/A genotype of À 536T4A SNP. The P-values were calculated with the w 2 test for the differences of IL12B mRNA levels between the asthmatic patients and the healthy controls with three different À 536T4A genotypes. (b) IL12B production was measured by ELISA in the blood serum from 36 allergic asthma patients and 28 controls carrying three different genotypes of À 536T4A SNP. The P-values were calculated with the Mann-Whitney U-test for the differences of IL12B protein production between the asthmatic patients and the healthy controls with three different À 536T4A genotypes. (Figure 3c ). With extracts of stimulated cells in particular, a high molecular weight complex was clearly visible with the À 536T, but not with the À 536A sequence, while a complex with increased mobility (marked with an arrow) was of equal intensity. These differences were confirmed with cross-competition experiments using unlabeled À 536T sequence, in combination with À 536T as a probe and nuclear proteins from activated Jurkat T cells (Figure 3c ). These data indicated that the T-to-A change at position À 536 of the C/EBPa sequence resulted in decreased binding of nuclear proteins.
Interaction analysis of À 536T4A of IL12B and C/EBPa expression levels Absence of C/EBPa in bronchial smooth muscle cells might associate with the development of asthma. 16, 17 Therefore, we investigated whether there was clinical relevance of IL12B and C/EBPa expression levels. We performed quantitative analysis of IL12B and C/EBPa mRNA levels from 18 asthmatic patients and 18 healthy controls carrying different promoter À 536 genotypes of IL12B gene. We found a significantly decreased expression of C/EBPa and IL12B in asthmatic patients compared with those of healthy controls (Figure 4) . Furthermore, we found a joint effect in both decreased expression of C/EBPa and gradient loss of IL12B expression of asthmatic patients carrying À 536TT genotypes, compared with genotype TA or AA (Figure 4 ). These data suggested that there might be an additive effect between C/EBPa and IL12B promoter SNP in asthma disease progression. A larger sample size of asthmatic cases and non-asthmatic controls is needed to conduct and confirm this joint effect.
DISCUSSION
Here we conducted a case-control study to screen potentially regulatory regions of IL12B, and identified a novel genetic variant ( À 536T4A) in the promoter region exhibiting evidence for association with asthma in Chinese populations. The association between À 536A allele and asthma was further confirmed in an independent case-control sample from the Henan province of China. We further found that the À 536AA genotype was associated with decreased regulation of IL12B mRNA levels and IL12B production. These results indicated that IL12B does exert a substantial influence on the inheritance of asthma in Chinese populations.
We further examined five other IL12B SNPs (c.677G4A, c. À 3580G4A, c.1146A4C, c.1582G4C and c.856-20C4T) in these asthmatic subjects, but there were no significant associations between these SNPs and asthma. Although positive associations of other polymorphisms within IL12B genes with asthma have been reported, [7] [8] [9] we failed to observe any association with susceptibility to asthma for these polymorphisms of IL12B. Several factors could provide plausible explanations, for example, (1) possible genetic differences between different ethnic populations, (2) small size of this study, like normal controls (n ¼ 144) and (3) different study designs and possible biases in recruiting case and controls in the studies. Therefore, validation of asthma risk-related IL12B promoter variation in a larger sample size of asthmatic patients or further test for the differences of IL12B and C/EBPa mRNA levels between the asthmatic patients and the healthy controls with three different À 536T4A genotypes.
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It is biologically plausible that reduced production of IL-12 could result in attenuation of Th1 function, leading to more intense Th2 responses. 15 In our study, the À 536T-to-A change in conjunction with the most distal C/EBP consensus sequence was located at the IL12B promoter. Further combined functional assay showed that IL12B À 536AA was associated with reduced regulation of IL12B production, and decreased binding of nuclear C/EBPa to the promoter region carrying À 536T4A polymorphism. Our current finding confirmed previous studies that reduced production of IL-12 protein was associated with asthmatic individuals. Therefore, our finding that À 536AA genotype mediated IL12B reduced expression in asthmatic individuals could predispose toward development of allergic asthma. We couldn't exclude the possibility that the association of the IL12B À 536T4A with asthma is a reflection of a linkage disequilibrium with another polymorphism in the 5q31 region. However, the observations that promoter À 536T4A leads to altered IL-12 production and decreased binding of nuclear proteins C/EBPa to this region, suggest that the polymorphism itself is involved in the genetic susceptibility to allergic asthma.
CCAAT-enhancer-binding proteins (C/EBPs) are a family of transcription factors composed of C/EBP-a, -b, -g, -d, -e and -z, which could promote the expression of certain genes through the interaction of the components of the basal transcription apparatus (RTTGCGYAAY, where R is A or G, and Y is C or T). 18 Many previous studies indicated that bronchial smooth muscle cells lacking C/EBPa were discovered in asthmatic patients. 16, 17, 19 This fine-tuned balance of C/EBP proteins controlled cell-cycle progression of bronchial smooth muscle cells and fulfilled a central role in maintaining lung integrity and tissue remodeling. 16, 17, 19 It is possible that downstream target genes of C/EBPa protein might be involved in asthma progression. 17, 19 Our electrophoretic mobility shift assay analysis showed that C/EBPa was the predominant protein comprising the DNA-binding complex of IL12B promoter in asthmatic patients. Our QPCR analysis indicated that C/EBPa was decreased in PBMCs of asthmatic patients when compared with those of healthy subjects. Likewise, a decreased C/EBPa DNA-binding activity with IL12B promoter was observed because of the presence of allele risk genotype À 536AA in IL12B promoter when compared with À 536TT genotype. However, it is still unknown whether there is another transcription factor preferentially binding to A allele promoter. Furthermore, our study discovered a joint effect in both decreased expression of C/EBPa and gradient loss of IL12B expression of asthmatic patients carrying À 536TT genotypes compared with genotype TA or AA. The ultimate goal of genetic studies will be the identification of combinations of several polymorphic genes that may cooperate, either independently or in synergy, to influence asthma phenotype.
In conclusion, our results suggest a potential role for IL12B gene promoter polymorphisms in asthma pathogenesis in Chinese populations. Importantly, our data provide a plausible final common pathway of C/EBPa decreasingly mediated À 536AA allele-type IL12B expression in asthma progression, which could be helpful in understanding the important function of IL12B in asthma development and in developing drugs to treat asthma.
MATERIALS AND METHODS
Sample collection and DNA/RNA preparations Patients and control subjects were recruited from Sir Run Run Shaw hospital, which is affiliated with Zhejiang University School of Medicine and Renji Hospital, which is affiliated with School of Medicine, Shanghai Jiaotong University. Among the subjects, there were 255 patients with asthma and 144 healthy controls. Out of the 255 patients, 133 cases are male, 122 cases are female, 193 are young patients (o18 years old) and 62 are adult patients (418 years old). All asthmatic patients had currently one or more symptoms, and physical examination results that were compatible with the asthma definition by the American Thoracic Society. 2 Normal healthy subjects were recruited from among the spouses of the patients and the general population who answered negatively to a screening questionnaire for respiratory symptoms and showed normal findings on a simple medical examination. Total serum IgE levels and levels of IgE specific for Dermatophagoides farinae (Df) were determined with the Pharmacia CAP System. In 85% informative patients, total IgE level is 4300 IU ml À 1 . After informed consent was obtained from all participating individuals and approval for this work was received from the institution ethics committee and it conformed to the tenets of the Declaration of Helsinki, blood samples were collected for genomic RNA/DNA extraction using the QIAmp Blood kit (Qiagen, Amtsgericht, Dusseldorf, Germany). To avoid gDNA contamination in RNAs, samples were treated with DNase I (Qiagen).
SNP screening and genotyping
To find common SNPs, we designed specific primer sets based on the IL12B sequences (NM_002187) to screen the exons and the flanking regions, including the promoter regions of IL12B gene. The screening panel included 25 affected asthmatic individuals. PCR conditions were set as previously reported. 20 PCR products sequencing was performed by PCRdirect sequencing using the ABI-3100 sequencer (Applied Biosystems, Foster City, CA, USA). We genotyped all discovered SNPs of IL12B gene from the subjects including 255 asthmatic patients and 144 unaffected individuals. Specific primers were designed based on genomic sequences obtained from the GenBank DNA database.
Quantitative real-time PCR Peripheral blood lymphocytes were separated from other blood components following the Ficoll method (Amersham, Uppsala, Swedan). The mRNA levels of IL12B or C/EBPa in peripheral blood lymphocytes from asthmatic patients and healthy controls were measured with real-time PCR using IL12B-specific primers as follows: 5-AGTAGTTATGGCTAAGGACATGA-3 (sense); 5-AGGGATTCCAGATTTTCTTTGCA-3 (antisense); C/EBPa-specific primers as follows: 5-TGGACAAGAACAGCAACGAGTAC-3 (sense); 5-GCAGTTGCCCATGGCCTTGAC-3 (antisense); 1 ml of cDNA was amplified for 42 cycles with a SYBR Green Supermix (Applied Biosystems) using a thermo cycler (MJ, Ramsey, MN, USA). Melting curve analysis was done at the end of the reaction to assess the quality of the final PCR products. The threshold cycle C(t) values were calculated by fixing the basal fluorescence at 0.05 unit. Three replicates were used for each sample, and the average C(t) value was calculated. The DC(t) values were calculated as C(t) sample À C(t) GAPDH. The N-fold increase or decrease in expression was calculated by the DDCt method. Serum IL12B detected by ELISA Serum IL12B levels were determined by ELISA according to the manufacturer's instructions (BD Biosciences, Shanghai, China). Optical densities were measured at 405-nm wavelength, and cytokine concentrations were calculated from the standard curve using recombinant human IL12B. Lower limit of detection for IL12B was 10 pg ml À 1 . Three independent experiments were performed to get the mean value with stand error of IL12B production (Mann-Whitney U statistics).
Constructs and reporter gene assay
To create the IL12B promoter-luciferase reporter constructs, the upstream region ( À 866 to þ 12) of IL12B was amplified and cloned into the pGL3-basic luciferase vector (Promega, Madison, WI, USA). To compare the activities of IL12B promoters containing promoter À 536AA and À 536TT alleles, À 536AA alleles were generated according to site-directed mutagenesis using the PCR primers (forward: 5-AGATGGGTGGTAAAAAGTATGTTTCTGAAA-3; reverse: 5-TTTCAGAAACATACTTTTTACCACCCATCT-3) using the Quickchange site-directed mutagenesis protocol (Stratagene, Santa Clara, CA, USA). Jurkat T cells were cultured for 24 h after transfection with the reporter gene vectors together with the C/EBP-a, -b and -g expression vectors, respectively. The cells were then maintained resting or activated with 10 ug ml À 1 LPS (Sigma, St Louis, MO, USA) with or without 10 U recombinant IFN-g (R&D, Minneapolis, MN, USA) per ml for 6 h and lysed. Luciferase activity was measured on a luminometer (Berthold, Bad Wildbad, Germany) using the Dual-Luciferase Reporter Assay System (Promega). The ratio of firefly luciferase to Renilla luciferase was calculated for each well.
IL12B and risk of allergic asthma Z Xu et al
Streptavidin-agarose pulldown and Western blotting
The pulldown assay was performed following a protocol described elsewhere, 21 with slight modification. Biotin-labeled allelic probes were incubated with equal amounts of nuclear extract from activated Jurkat T cells for 2 h at room temperature, in the presence of streptavidin-agarose beads (GE Healthcare, Pittsburgh, PA, USA) and protein inhibitors. The precipitated protein-DNA complex was dissociated from the agarose beads by suspending the pellet in Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) and heating it. The supernatants were then subjected to SDS-PAGE. The proteins were transferred onto a PVDF membrane (Bio-Rad), blotted with an anti-C/EBPa antibody and detected with ECL solution (Pierce, Rockford, IL, USA).
Nuclear extract preparation and electrophoretic mobility shift assay Jurkat T cells were stimulated with 10 ug per ml of LPS with or without IFN-g or left unstimulated at a density of 5 Â 10 6 per ml for 24 h. Nuclear extracts were prepared by the standard protocol. Binding reactions were carried out as previously described with minor modifications; binding reactions contained 5-15 mg nuclear protein, 5 mm Tris-HCl, pH 7.5, 100 mm NaCl, 1 mm EDTA, 1 mm DTT, complete protease inhibitor (Roche, Basel, Switzerland), and 5% glycerol in a total volume of 25 ml. The following probes were used: À 536A (5-gatcCCAAGATGGGTGGTAAAAAG-TATGTTCTG-3), À 536-T (5-gatcCCAAGATGGGTGGTAAAATGTATGTTCTG-3) and C/EBPa mutant binding site (5-gatcCCAAGATGCGATAGGCGATA-TATGTTCTG-3) oligonucleotides. Complexes were separated on 4% polyacrylamide gels.
Statistical analysis
Genetic association and the Hardy-Weinberg equilibrium for the distribution of genotypes were tested by w 2 analysis with Yates' correction. Odds ratios were calculated with 95% confidence intervals. The pairwise linkage disequilibrium coefficient r 2 was calculated using the program Haploview. Frequencies of different genotypes were compared in the Fisher's exact test. For comparison of serum IL12B production in different genotype groups, we used the Mann-Whitney U-test. Two-tailed P-value o0.05 was considered statistically significant.
